David E Watson
Overview
Explore the profile of David E Watson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corkum C, Wiede L, Ruble C, Qiu J, Mulrooney-Cousins P, Steeves M, et al.
Front Microbiol
. 2022 Dec;
13:1011070.
PMID: 36560951
Woodchuck infected with woodchuck hepatitis virus (WHV) is the most pathogenically compatible naturally occurring model of human hepatitis B virus (HBV) infection, chronic hepatitis B, and HBV-induced hepatocellular carcinoma. This...
2.
Watson D, Hunziker R, Wikswo J
Exp Biol Med (Maywood)
. 2017 Oct;
242(16):1559-1572.
PMID: 29065799
Microphysiological systems (MPS), which include engineered organoids (EOs), single organ/tissue chips (TCs), and multiple organs interconnected to create miniature in vitro models of human physiological systems, are rapidly becoming effective...
3.
Ali A, Watson D
Pharmacotherapy
. 2017 Sep;
37(11):1383-1390.
PMID: 28950039
Study Objective: Ipilimumab, pembrolizumab, and nivolumab are checkpoint inhibitors (CPIs) that activate T-cell-mediated immune response. CPI can provide durable benefits to some cancer patients with melanoma, renal cell cancer, non-small...
4.
Kazda C, Ding Y, Kelly R, Garhyan P, Shi C, Lim C, et al.
Diabetes Care
. 2017 Apr;
40(6):808.
PMID: 28420698
No abstract available.
5.
Kazda C, Ding Y, Kelly R, Garhyan P, Shi C, Lim C, et al.
Diabetes Care
. 2016 Dec;
39(11):e199-e200.
PMID: 27926898
No abstract available.
6.
Smith A, Calley J, Mathur S, Qian H, Wu H, Farmen M, et al.
BMC Genomics
. 2016 Sep;
17:694.
PMID: 27576563
Background: MicroRNAs (miRNA) are ~19-25 nucleotide long RNA molecules that fine tune gene expression through the inhibition of translation or degradation of the mRNA through incorporation into the RNA induced...
7.
Burch P, Greg Hall D, Walker E, Bracken W, Giovanelli R, Goldstein R, et al.
Toxicol Sci
. 2016 Jan;
150(1):247-56.
PMID: 26721300
Novel skeletal muscle (SKM) injury biomarkers that have recently been identified may outperform or add value to the conventional SKM injury biomarkers aspartate transaminase (AST) and creatine kinase (CK). The...
8.
Kazda C, Ding Y, Kelly R, Garhyan P, Shi C, Lim C, et al.
Diabetes Care
. 2015 Dec;
39(7):1241-9.
PMID: 26681715
Objective: Type 2 diabetes pathophysiology is characterized by dysregulated glucagon secretion. LY2409021, a potent, selective small-molecule glucagon receptor antagonist that lowers glucose was evaluated for efficacy and safety in patients...
9.
Engle S, Watson D
Toxicol Sci
. 2015 Nov;
149(2):458-72.
PMID: 26609138
Cardiovascular (CV) toxicity is an important cause of failure during drug development. Blood-based biomarkers can be used to detect CV toxicity during preclinical development and prioritize compounds at lower risk...
10.
Pritt M, Hall D, Jordan W, Ballard D, Wang K, Muller U, et al.
Toxicol Sci
. 2014 Jul;
141(2):398-408.
PMID: 25015659
Detection of compound-related neurodegeneration is currently limited to brain histopathology in veterinary species and functional measurements such as electroencephalography and observation of clinical signs in patients. The objective of these...